1. Home
  2. SY vs NGEN Comparison

SY vs NGEN Comparison

Compare SY & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo So-Young International Inc. American Depository Shares

SY

So-Young International Inc. American Depository Shares

HOLD

Current Price

$3.15

Market Cap

323.8M

Sector

Technology

ML Signal

HOLD

NGEN

NervGen Pharma Corp. Common stock

N/A

Current Price

$3.98

Market Cap

317.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SY
NGEN
Founded
2013
2017
Country
China
Canada
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
323.8M
317.6M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
SY
NGEN
Price
$3.15
$3.98
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$5.50
N/A
AVG Volume (30 Days)
340.6K
101.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
0.79%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$6.36
N/A
Revenue Next Year
$57.24
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.67
$3.55
52 Week High
$6.28
$5.93

Technical Indicators

Market Signals
Indicator
SY
NGEN
Relative Strength Index (RSI) 51.74 45.04
Support Level $2.80 $3.69
Resistance Level $3.33 $4.44
Average True Range (ATR) 0.17 0.28
MACD 0.01 0.02
Stochastic Oscillator 63.33 51.79

Price Performance

Historical Comparison
SY
NGEN

About SY So-Young International Inc. American Depository Shares

So-Young International Inc is an online destination for discovering, evaluating, and reserving medical aesthetic services in China. Its business model comprises four integrated components: professional content and its distribution through social media networks and its targeted media platforms in China, a social community characterized by signature user-generated content, Online reservation services for a medical aesthetic treatment, and the research, development, production, sales and agency of laser and other optoelectronic medical beauty equipment. It generates revenue from information services fees and reservation services fees from medical aesthetic service providers.

About NGEN NervGen Pharma Corp. Common stock

NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.

Share on Social Networks: